CARL ZEISS MEDITEC AG 
'A strong fourth quarter and tailwind from the exchange rates of major currencies supported the good operating result. In contrast to the positive currency effects on operating result, we had to accept charges from currency hedging and write-downs in the financial result,' says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
Key figures by business unit at a glance
Once again, the strategic business unit (SBU) Surgical Ophthalmology achieved the strongest growth in the fiscal year. Revenue increased by 22.5 percent (adjusted for currency effects 19.0 percent), to € 355.3 million (prior year: € 290.0 million). Business was driven both by good demand for intraocular lenses and consumables for cataract surgery and for surgical workstations for ophthalmology.
Revenue of the Ophthalmic Systems SBU increased by 12.2 percent (adjusted for currency effects, 3.9 percent), to € 392.0 million (prior year: € 349.3 million). As in the previous quarters, the area of diagnostics suffered from price and competitive pressure, while the refractive laser business for the correction of vision defects, including per-procedure business in this segment, performed very well.
The Microsurgery SBU benefited significantly from currency effects in the reporting period, with revenue growth of 8.5 percent, to € 292.8 million (prior year: € 270.0 million). After adjustment, this growth would equate to 2.7 percent. Business in Japan, in particular, which is especially important for this business unit, declined compared with a strong figure in the prior year.
Revenue by region
The Company's revenue was boosted by growth in all three of its global regions; however, after adjustment for currency effects, the highest growth rate was once again recorded in the Asia/Pacific region.
The development of the individual markets in the region Europe, Middle East and Africa (EMEA) region was heterogeneous. Germany and the UK were the main growth drivers, with a revenue increase of 9.4 percent, to € 358.8 million. Bolstered by the strong dollar, revenue in the Americas region increased by 21.9 percent, to € 361.9 million Adjusted for currency effects, this region grew by 6.0 percent. At € 319.4 million, revenue in the Asia/Pacific (APAC) region was up by 12.3 percent year-on-year (adjusted for currency effects: 10.1 percent). High growth rates in China and India more than compensated in this region for a downturn in the Japanese market.
The Company's financial result was curbed by non-operating effects: due to the current strength of the dollar against the euro, currency hedging costs impacted earnings per share just as much as charges from strategic investments. Earnings per share (EPS) decreased accordingly by around 17 percent compared with the prior year.
'We are satisfied with the results for the fiscal year. In spite of a difficult market environment, we once again succeeded in winning market shares in a number of markets,' says Ludwin Monz. According to Dr. Monz, the Company can be expected to grow at least as fast as the underlying markets in the coming fiscal year - with an EBIT margin that should be within the range of 13-15 percent in 2015/16 and in the medium term.
Revenue by strategic business unit
| Figures in EUR '000 | FY 2013/2014 | FY 2014/2015 |
Change from prior year |
Change from prior year¹ |
| Ophthalmic Systems | 349,314 | 391,958 | +12.2% | +3.9% |
| Surgical Ophthalmology | 289,984 | 355,267 | +22.5% | +19.0% |
| Microsurgery | 269,957 | 292,836 | + 8.5% | + 2.7% |
¹ adjusted for currency effects
Revenue by region
| Figures in EUR '000 | FY 2013/2014 | FY 2014/2015 |
Change from prior year |
Change from prior year¹ |
| EMEA | 328,063 | 358,753 | + 9.4% | + 8.9% |
| Americas | 296,781 | 361,882 | + 21.9% | + 6.0% |
| APAC | 284,411 | 319,426 | + 12.3% | + 10.1% |
¹ adjusted for currency effects
Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-332
press.meditec@zeiss.com
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company supplies innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec AG's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy. In fiscal year 2014/2015 (ended 30 September) the Group's approx. 2,900 employees generated revenue of almost € 1,040 million.
The head office of Carl Zeiss Meditec Group is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application & Research India (CARIn) in Bangalore, India and the ZEISS Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For more information visit our website at:
www.zeiss.com/meditec
Number: 0153-2015-ENG OP
Number of Words: 1118
Number of Characters: 9300
|
distributed by
|
